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AbstrACt
Objectives This meta-analysis of randomised placebo-
controlled clinical trials aimed to assess the effect of 
fenofibrate on apolipoprotein C-III (apo C-III), a key 
regulator of triglyceride metabolism.
Materials and methods Randomised placebo-controlled 
trials investigating the impact of fenofibrate treatment 
on apo C-III levels were searched in PubMed-Medline, 
Scopus, Web of Science and Google Scholar databases 
from inception to 18 August 2017. Quantitative data 
synthesis was determined by a random-effects model and 
generic inverse variance method. Sensitivity analysis was 
conducted using the leave-one-out method. A weighted 
random-effects meta-regression was performed to 
evaluate glycaemic parameter confounders.
results Meta-analysis of 10 clinical trials involving 477 
subjects showed fenofibrate therapy decreased apo C-III 
levels (weighted mean difference (WMD) −4.78 mg/dL, 
95% CI −6.95 to –2.61, p<0.001; I266.87%). Subgroup 
analysis showed that fenofibrate reduced plasma apo 
C-III concentrations in subgroups of trials with treatment 
durations of either <12 weeks (WMD −4.50 mg/dL, 
p=0.001) or ≥12 weeks (WMD: −4.73 mg/dL, p=0.009) 
and doses of fenofibrate <200 mg/day (WMD −6.33 mg/dL, 
p<0.001) and >200 mg/day (p=0.006), with no significant 
difference between the subgroups.
Conclusion This meta-analysis found that fenofibrate 
therapy significantly decreases apo C-III levels, an effect 
evident with both short-term treatment and doses less 
than 200 mg/day.
IntrOduCtIOn 
Elevated triglycerides have been shown to be 
an independent marker of coronary artery 
disease (CAD).1–3 Apolipoprotein C-III (apo 
C-III) is a key regulator of triglyceride metab-
olism that mediates its effects through lipo-
protein lipase (LPL) inhibition. However, 
indirect LPL-independent mechanisms are 
also present, shown by inhibition of apo C-III 
messenger RNA and a reduction of apo C-III 
levels in patients with LPL deficiency.4 5 Apo 
C-III also inhibits hepatic lipase activity that 
decreases the conversion of very-low-density 
lipoprotein (VLDL) to intermediate-density 
lipoprotein (IDL) and low-density lipopro-
tein (LDL).6 Recently, apo C-III was shown 
to be significantly associated with incident 
CAD in the European Prospective Investiga-
tion of Cancer (EPIC)-Norfolk prospective 
population study.7 It has been suggested that 
apo C-III may exert atherogenic properties 
by both direct (via enhancing inflammation) 
and indirect (via promoting hypertriglyceri-
daemia) mechanisms.8 
Fibrates are a therapeutic class of drugs that 
are used primarily for the treatment of hyper-
triglyceridaemia, but are also for combined 
dyslipidaemias in which both triglycerides and 
LDL-cholesterol (LDL-C) are elevated.9–11 
Fibrates also have several pleiotropic activities 
described recently.12–18 Fenofibrate is the most 
commonly used fibrate that induces lipopro-
tein lipolysis, fatty acid uptake and increase 
high-density lipoprotein (HDL) produc-
tion,19 20 while reducing plasma triglyceride 
levels by 20%–30%.21 Mechanistically, feno-
fibrate activates peroxisome proliferator acti-
vated receptor alpha through modulation 
of genes expression related to fatty acid and 
lipoprotein metabolism.22–24
strengths and limitations of this study
 ► This was the first systematic review to determine 
the effect of fenofibrate on plasma apolipoprotein 
C-III (apo C-III).
 ► The strength of this study was the use of the me-
ta-analysis that used the increased population size 
compared with individual studies that were small 
and, in some instances, underpowered to discern if 
fenofibrate had an effect on plasma apo C-III.
 ► The limitation was that the small number of trials, 
lack of studies in patients with hyperapolipoprotein-
aemia C-III and lack of presenting gender-stratified 
results by individual studies.
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This meta-analysis of randomised placebo-controlled 
clinical trials using fenofibrate therapy aimed to deter-
mine its effect on apo C-III levels.
MethOds
search strategy
This study was designed according to the guidelines of 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement.25 PubMed-Medline, Scopus and 
ISI Web of Knowledge databases were searched using the 
following search terms in titles and abstracts: fenofibrate 
AND (apoCIII OR apoC-III OR ‘apo CIII’ OR ‘apo C-III’ 
OR apoC3 OR ‘apo C3’) AND (placebo OR placebo-con-
trolled). The wild-card term ‘*’ was used to increase 
the sensitivity of the search strategy. An example of the 
search strategy employed in PubMed-Medline is shown in 
online supplementary file 1. The search was limited to 
articles published in English language. The literature was 
searched from inception to 18 August 2017.
study selection
Original studies were included if they met the following 
inclusion criteria: (1) being a randomised placebo-con-
trolled clinical trial with either parallel or cross-over 
design, (2) investigating the impact of fenofibrate versus 
placebo on total circulating concentrations of apo C-III 
and (3) presentation of sufficient information on apo C-III 
concentrations at baseline and at study end in both inter-
vention and placebo groups or providing the net change 
values. Exclusion criteria were: (1) non-clinical studies; 
(2) uncontrolled or non-placebo-controlled studies; (3) 
observational studies with case–control, cross-sectional 
or cohort design; (4) reporting postprandial plasma 
apo C-III levels and (5) lack of sufficient information on 
baseline or follow-up total circulating apo C-III levels.
data extraction
Eligible studies were reviewed and the following data 
were abstracted: (1) first author’s name; (2) year of publi-
cation; (3) country where the study was performed; (4) 
study design; (5) number of participants in the statin 
and control groups; (6) fenofibrate dose; (7) duration of 
treatment; (8) age, gender and body mass index (BMI) 
of study participants and (9) baseline and follow-up 
concentrations of plasma lipids, lipoproteins and apoli-
poproteins including apo C-III. When apo C-III data were 
incompletely reported, authors of the respective article 
were contacted to obtain missing information. Two 
authors (AS and LES) reviewed the papers, and disagree-
ments were resolved through discussion and consultation 
with a third author (SLA).
Quality assessment
The quality of involved studies in this meta-analysis was 
evaluated using the Cochrane criteria. Risk of bias in the 
studies considered in this meta-analysis was evaluated 
according to the Cochrane instructions.26
Quantitative data synthesis
Meta-analysis was conducted using Comprehensive 
Meta-Analysis V.2 software (Biostat, New Jersey, USA). 
A random-effects model (using DerSimonian-Laird 
method) and the generic inverse variance weighting 
method were used to compensate for the heterogeneity 
of studies in terms of study design, treatment duration 
and the characteristics of populations being studied. SDs 
of [(SDpre-treatment)
2 + (SDpost-treatment)
2 – (2R × SDpre-treatment × 
SDpost-treatment)], assuming a correlation coefficient (r)=0.5. 
Where SE of the mean (SEM) was only reported, SD was 
estimated using the following formula: SD=SEM ×  sqrt 
(n), where n is the number of subjects. Heterogeneity was 
assessed quantitatively using Cochrane Q and I2 statistic. 
All apo C-III values were collated in mg/L. Effect sizes 
were expressed as weighted mean difference (WMD) and 
95% CI. In order to avoid the double-counting problem 
in trials comparing multiple treatment arms versus a 
single control group, the number of subjects in the 
control group were divided by the number of treatment 
arms. In order to evaluate the influence of each study on 
the overall effect size, a sensitivity analysis was conducted 
using the leave-one-out method (ie, removing one study 
each time and repeating the analysis).27 28
Meta-regression
As potential confounders of treatment response, the 
duration of treatment and baseline plasma apo C-III 
concentrations were entered into a random-effects 
meta-regression model to explore their association with 
the estimated effect size on plasma apo C-III levels.
Publication bias
Evaluation of funnel plot, Begg’s rank correlation and 
Egger’s weighted regression tests were performed to 
assess the presence of publication bias in the meta-anal-
ysis. When there was evidence of funnel plot asymmetry, 
potentially missing studies were imputed using the ‘trim 
and fill’ method.29 In case of a significant result, the 
number of potentially missing studies required to make 
the p value non-significant was estimated using the ‘fail-
safe N’ method as another marker of publication bias.
Patient and public involvement
No patients or public were involved in this study.
results
Overall, 61 articles were found following multidatabase 
search. After screening of titles and abstracts, 22 arti-
cles were assessed in full text. Of these five articles were 
excluded because of lack of reporting serum/plasma 
total apo C-III concentrations, four because of duplicate 
reporting of data from the same population, two because 
of reporting postprandial apo C-III levels and one 
because of incomplete data on apo C-III levels. There-
fore, 10 articles were found to be eligible for inclusion in 
the meta-analysis (figure 1).
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study characteristics
Data were pooled from 10 randomised placebo-con-
trolled clinical trials comprising a total of 477 subjects, 
including 265 and 212 participants in the fenofibrate 
and placebo arms respectively (individuals of the cross-
over trials were considered in the treatment and control 
groups).30–40 Clinical trials reported different doses of 
fenofibrate. The included studies were published between 
200234 38 and 2016. Treatment duration ranged from 
2 weeks36 40 to 12 weeks.30–34 Study designs of included trials 
were parallel30 34 36 41 and crossover.31 33 35 37–40 Selected 
studies enrolled subjects with metabolic syndrome,30 
type 2 diabetes,31 33 hypertriglyceridaemia,32 35 38 dyslipi-
daemia34 36 and non-diabetic subjects.40 Characteristics of 
the included clinical trials are presented in table 1.
risk of bias assessment
Most of the included studies showed insufficient informa-
tion regarding the sequence generation and allocation 
concealment. Moreover, three trials had high risk of 
bias concerning blinding of participants, personnel and 
outcome assessors.36 40 Nevertheless, all selected studies 
were characterised by a low risk of bias for incomplete 
outcome data and selective outcome reporting. Details of 
the risk of bias assessment are shown in table 2.
Quantitative data synthesis
The present meta-analysis of data from 11 randomised 
placebo-controlled trials found a significant reduction of 
apo C-III plasma concentrations following treatment with 
fenofibrate (WMD: −4.56 mg/dL, 95% CI −6.53 to –2.58, 
p<0.001; I2 64.67%) (figure 2). The effect size was robust 
in the leave-one-out sensitivity analysis (figure 2) and 
not mainly driven by any single study. Subgroup analysis 
showed significant decreases in plasma apo C-III levels 
caused by fenofibrate in subgroups of trials with treat-
ment durations of either <12 weeks (WMD −4.48 mg/dL, 
95% CI −7.32 to –1.64, p=0.002; I2 70.74%) or ≥12 weeks 
Figure 1 Flow chart of the number of studies identified and included into the meta-analysis. Apo C-III, apo C-III.
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(WMD −5.66 mg/dL, 95% CI −10.15 to –1.16, p=0.014; I2 
69.61%), with no significant difference between the two 
subgroups (p=0.664). With respect to fenofibrate dose, 
significant reductions were observed in both subgroups 
of trials with administered doses of <200 mg/day (WMD 
−6.33 mg/dL, 95% CI −10.38 to –2.27, p=0.002; I2 
83.26%) and ≥200 mg/day (WMD −3.47 mg/dL, 95% CI 
−5.51 to –1.42, p=0.001; I2 27.51%). Again, there was no 
Table 2 Quality of bias assessment of the included studies according to the Cochrane guidelines
Study
Sequence 
generation
Allocation 
concealment
Blinding of 
participants, 
personnel and 
outcome assessors
Incomplete 
outcome data
Selective 
outcome 
reporting
Other sources 
of bias
Belfort et al30 L U U L L U
Chan et al31 U U U L L U
Davidson et al32 U U U L L U
Ishibashi et al34 L U U L L U
Kazumi et al35 U U U L L U
Kosoglou et al36 U U H L L U
Ooi et al37 U U U L L U
Sasaki et al38 U L U L L U
Vega et al39 U U H L L U
Wagner et al40 U U H L L U
H, high risk of bias; L, low risk of bias; U, unclear risk of bias.
Figure 2 Forest plot displaying weighted mean difference and 95% CIs for the effects of fenofibrate on circulating 
apolipoprotein C-III concentrations. The lower plot shows the results of leave-one-out sensitivity analysis. Analyses were 
performed using a random-effects model.
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significant difference between the subgroups treated with 
different fenofibrate doses (p=0.217) (figure 3).
Meta-regression
Random-effects meta-regression was performed to assess 
the impact of potential confounders on the effects of feno-
fibrate on plasma apo C-III levels. The results suggested 
a significant association between the apo C-III-lowering 
effect of fenofibrate with baseline apo C-III (slope −0.40; 
95% CI −0.58 to –0.22; p<0.001) and baseline triglyceride 
(slope −0.02; 95% CI −0.03 to –0.01; p=0.001) concen-
trations. However, no significant association between 
the apo C-III-lowering and triglyceride-lowering effects 
of fenofibrate was found (slope 0.11; 95% CI −0.05 to 
0.27; p=0.185) nor were there any association with base-
line LDL-C (slope −0.02; 95% CI −0.12 to 0.08; p=0.677), 
HDL-cholesterol (HDL-C) (slope 0.35; 95% CI −0.29 to 
0.98; p=0.284) and BMI (slope −0.75; 95% CI −2.08 to 
0.58; p=0.269).
Publication bias
Visual inspection of Begg’s funnel plots revealed a slight 
asymmetry in the meta-analysis of fenofibrate’s effect on 
plasma apo C-III levels that was imputed by one poten-
tially missing study at the left side of the plot using ‘trim 
and fill’ method that yielded an adjusted effect size of 
−5.18 (−7.28 to –3.09) (figure 4). Begg’s rank correlation 
(p=0.592) and Egger’s regression (p=0.718) tests did not 
suggest the presence of publication bias. The results of 
‘fail-safe N’ test suggested that 153 missing studies would 
be required to make the observed significant result 
non-significant.
dIsCussIOn
In this meta-analysis of randomised placebo-controlled 
clinical trials, fenofibrate therapy was related to a signif-
icant reduction of apo C-III levels. Subanalyses revealed 
that this effect was observed even in those trials whose 
duration was less than 12 weeks and for doses of feno-
fibrate both higher and lower than 200 mg/day. More-
over, the apo C-III-lowering effect of fenofibrate was 
found to be directly proportional to baseline apo C-III 
and triglycerides levels, suggesting that greater effects 
on plasma apo C-III levels are anticipated in popula-
tions with hyperapolipoproteinaemia C-III hypertriglyce-
ridaemia. However, there were no associations between 
apo C-III-lowering effect of fenofibrate with baseline 
BMI, LDL-C and HDL-C, and the changes in plasma 
triglycerides levels. The latter finding on the lack of any 
association between changes in plasma apo C-III and 
Figure 3 Forest plot displaying weighted mean difference and 95% CIs for the effects of different doses (<200 mg/day 
vs ≥200 mg/day) and durations (<12 weeks vs ≥12 weeks) of treatment with fenofibrate on circulating apolipoprotein C-III 
concentrations. Analyses were performed using a random-effects model.
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triglycerides levels could be attributed to the fact that not 
all VLDL particles (as the main carriers of apo C-III in 
plasma) contain apo C-III. It has been estimated that apo 
C-III is present in about 50% of plasma VLDL particles. 
This might justify the lack of apo C-III reduction propor-
tional to triglycerides reduction following fenofibrate 
therapy.42
The reduction of apo C-III levels by fenofibrate therapy may 
contribute to a reduced risk of CAD achieved with fibrates 
therapy43–45; however, the mechanism(s) by which apo C-III 
increases CAD risk remain(s) unclear.7 Loss of function 
mutations of the APOC3 gene are associated with reduced 
triglyceride and VLDL levels,46 whereas genetic variations 
have linked APOC3 to CAD risk.47 Epidemiological studies 
have found an association between increased apo C-III and 
CAD that correlated with elevated triglyceride levels.7 48–50 
It has also been shown that accumulation of apo C-III and 
triglycerides in the necrotic core predisposes to plaque 
vulnerability in patients with stable CAD51; hence, the signif-
icant lowering effect of fenofibrate on both of these param-
eters might justify its potential efficacy in preventing plaque 
rupture and acute CV events, as shown for statin therapy.52 
In addition, there is evidence in vivo showing the stabilising 
and regressing effects of fenofibrate53 54 on the atheroscle-
rotic plaque. It has been shown that elevated triglycerides 
and low HDL-C are not only associated with macrovascular 
atherosclerotic changes such as CAD, but they are also risk 
factors for microvascular disease in type 2 diabetes mellitus.43 
Indeed, in addition to the association with elevated triglycer-
ide-rich particles such as VLDL number and size, increased 
apo C-III levels were also related to increased IDL particles 
numbers and a shift to more atherogenic small dense LDL 
particles.7 20 Small dense LDL exerts atherogenic properties 
and has been linked to increased cardiovascular risk as well 
as to the presence of metabolic disorders including obesity, 
metabolic syndrome and type 2 diabetes.55–57 Some specu-
late that it is quite unlikely that elevated triglycerides per se 
might be associated with an increased risk of CAD. However, 
triglyceride-rich particles such as VLDL and IDL could accu-
mulate in the intima, and can be further catabolised and 
ingested by macrophages to form foam cells, resulting in 
progression of the atherosclerotic lesion.58 Apo C-III may 
therefore be seen as a therapeutic target to reduce CAD, and 
antisense RNA inhibition has shown dramatic decreases in 
triglyceride levels.4 5
In the EPIC study, mediation analysis showed that a 
large part of the increased CAD risk associated with apo 
C-III was attributable to the triglyceride-rich remnant 
particle levels.7 This fits well with the mechanism proposed 
above. It has been also proven that fenofibrate decreases 
triglyceride-rich remnant particles.59 60 However, it was 
also shown that apo C-III was associated with an increased 
C reactive protein, a marker of inflammation that may 
represent an independent predictor of increased CAD 
risk.61 This finding may also reflect the LPL-independent 
mechanism of increased CAD risk by apo C-III.
The present meta-analysis suggested that the effect of 
apo C-III lowering was relatively rapid as it was observed 
within 12 weeks, thus indicating the early potential benefit 
of fibrate therapy. However, no data exist that relate 
triglycerides reduction and remnant particles changes 
induced by apo C-III. Of note, the reduction of apo C-III 
levels was also observed with fenofibrate doses <200 mg/
day, but it is unclear whether a reduction in apo C-III may 
Figure 4 Random-effects funnel plot detailing publication bias in the studies reporting the impact of fenofibrate on plasma apo 
C-III concentrations.
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occur even if in the absence of a therapeutic decrease in 
triglyceride levels.
The main limitation of the present meta-analysis is that 
several trials were characterised by a small population 
size and a limited number of individuals. However, the 
pooled population analysed was sufficiently robust due 
to other studies that provided a large population size. In 
addition, included studies did not define elevated plasma 
apo C-III levels among the inclusion criteria and hence 
future trials specifically defined in populations with 
hyperapolipoproteinaemia C-III might be interesting. 
Finally, included the trials did not provide gender-strat-
ified results for the impact of fenofibrate on plasma apo 
C-III levels; therefore, the presence of any gender effect 
on the apo C-III-lowering activity of fenofibrate needs to 
be evaluated in further studies.
Conclusion
The results of the present meta-analysis showed that feno-
fibrate treatment significantly decreases apo C-III levels, 
even with short-term treatment and doses <200 mg daily.
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